Crohn's disease in a southern European country: Montreal classification and clinical activity
✍ Scribed by Fernando Magro; Francisco Portela; Paula Lago; João Ramos de Deus; Ana Vieira; Paula Peixe; Isabelle Cremers; José Cotter; Marília Cravo; Lourdes Tavares; Jorge Reis; Raquel Gonçalves; Horácio Lopes; Paulo Caldeira; Paula Ministro; Laura Carvalho; Luis Azevedo; Altamiro Da Costa-Pereira
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 117 KB
- Volume
- 15
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
✦ Synopsis
Background: Given the heterogeneous nature of Crohn's disease (CD), our aim was to apply the Montreal Classification to a large cohort of Portuguese patients with CD in order to identify potential predictive regarding the need for medical and/or surgical treatment.
Methods:
A cross-sectional study was used based on data from an on-line registry of patients with CD.
Results:
Of the 1692 patients with 5 or more years of disease, 747 (44%) were male and 945 (56%) female. On multivariate analysis the A2 group was an independent risk factor of the need for steroids (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.1-2.3) and the A1 and A2 groups for immunosuppressants (OR 2.2; CI 1.2-3.8; OR 1.4; CI 1.0 -2.0, respectively). An L3ϩL3 4 and L 4 location were risk factors for immunosuppression (OR 1.9; CI 1.5-2.4), whereas an L1 location was significantly associated with the need for abdominal surgery (P Ͻ 0.001). After 20 years of disease, less than 10% of patients persisted without steroids, immunosuppression, or surgery. The Montreal Classification allowed us to identify different groups of disease severity: A1 were more immunosuppressed without surgery, most of A2 patients were submitted to surgery, and 52% of L1ϩL1 4 patients were operated without immunosuppressants.
Conclusions:
Stratifying patients according to the Montreal Classification may prove useful in identifying different phenotypes with different therapies and severity. Most of our patients have severe disease.
📜 SIMILAR VOLUMES
Background: Infliximab (IFX) is a chimeric (mouse/human) anti-TNF-alpha monoclonal antibody approved for the treatment of refractory luminal and fistulizing Crohn's disease (CD). It is a source of potential immunogenicity for humans, with the occurrence of anti-infliximab antibodies (ATIs), which ar
Background: Patients with clinically active Crohn's disease (CD), defined by a Crohn's Disease Activity Index (CDAI) Ͼ150, may have normal C-reactive protein (CRP) serum levels. In such cases, it is difficult to know whether these patients have really active disease or rather functional symptoms. Th
## Background: Long-term enteral nutrition may maintain clinical and endoscopic remission in patients with crohn's disease (cd). the aim of this prospective study was to investigate the impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal tissue cytokines
## Abstract ## Purpose To determine the feasibility of T1‐mapping and calculation of Gadolinium‐values in luminal Crohn's Disease (CD). ## Materials and Methods Nine patients with active CD were included. For each patient disease activity was determined, based on endoscopic and histopathological